HER2 alterations across solid tumors: implications for comprehensive testing
The Oncologist · 01.09.2025 · 30 (9)
DOI: 10.1093/oncolo/oyaf258 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 19.08.2025. Verfasst von Ahmed Ismail und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology & Oncology, Department of Medicine, The University of Alabama at Birmingham and O'Neal Comprehensive Cancer Center, Birmingham,…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AstraZeneca, UAB O'Neal Comprehensive Cancer Center.
Abstract (Originalsprache)
Purpose
ERBB2 (HER2) alterations (eg, overexpression, amplification, and mutations) are known to drive tumor progression. These changes, particularly in non-breast and gastric/gastroesophageal cancers, remain poorly characterized. With pan-tumor approval of HER2-targeted therapies like Trastuzumab deruxetecan (T-DXd), understanding ERBB2 alterations across diverse cancers is crucial.
Methods
HER2 analysis was conducted on 653 solid tumor specimens at the University of Alabama, using immunohistochemistry (IHC), copy number (CN) variation (CNV) assessment, and mutational profiling. The correlation between CN amplification and IHC expression was evaluated using Somers’ D ordinal association.
Results
Of the 653 cases, HER2 IHC scores were distributed as 3+ (3.1%), 2+ (13.2%), and 1+ (19.8%), with 63.9% being IHC-negative. ERBB2 CN amplification was observed in 3.1%, with 75% exhibiting IHC3+. Pathogenic mutations were found in 3.1%, with low IHC3+ rates (5%). Among samples with ERBB2 mutations, only 3 had CN amplifications (1-positive, 2-intermediate). Somers’-D analysis revealed a strong association between CNV and IHC expression (D = 0.73, P < .001).
Conclusion
This study highlights ERBB2 alterations across diverse cancers, demonstrating their heterogeneity and clinical significance. ERBB2 mutation-carrying tumors are less likely to have HER2 protein 3+ expression or CN amplification, indicating the need for comprehensive genomic analysis to identify those patients. In the context of pan-tumor approval of T-DXd for HER2, findings support integrating genomic and phenotypic data to enhance diagnostic precision and inform therapeutic decision-making. Comprehensive ERBB2 (HER2) testing across tumor types is essential to expand access to HER2-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology & Oncology, Department of Medicine, The University of Alabama at Birmingham and O'Neal Comprehensive Cancer Center, Birmingham, AL 35233, United States.
- Department of Medicine, Eastern Virginia Medical School at Old Dominion University, Norfolk, VA 23507, United States.
- Division of Oncology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, United States.
- Division of General Internal Medicine and Population Science, Department of Medicine and O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL 35233, United States.
- Caris Life Sciences, Phoenix, AZ 85040, United States.
- Division of Gynecologic Oncology, Department of OBGYN, The University of Alabama at Birmingham and O'Neal Comprehensive Cancer Center, Birmingham, AL 35233, United States.
ORCID-Profile: Ahmed Ismail, Arnab Basu, Sejong Bae, Aakash Desai
Förderung
- NCI NIH HHS
- AstraZeneca
- UAB O'Neal Comprehensive Cancer Center
- UAB O’Neal Comprehensive Cancer Center
Zitieren
APA
Ismail, A., Jani, C., Jahan, N., Midhun, M., Basu, A., Gupta, G., El-Rayes, B., Bae, S., Mattox, T., Hawkins, C., Arend, R. C., Akce, M., Boumber, Y., & Desai, A. (2025). HER2 alterations across solid tumors: implications for comprehensive testing. The Oncologist, 30(9). https://doi.org/10.1093/oncolo/oyaf258
Vancouver
Ismail A, Jani C, Jahan N, Midhun M, Basu A, Gupta G, et al. HER2 alterations across solid tumors: implications for comprehensive testing. The Oncologist. 2025;30(9). doi:10.1093/oncolo/oyaf258
BibTeX
@article{Ismail2025,
author = {Ismail, Ahmed and Jani, Chimay and Jahan, Nusrat and Midhun, Malla and Basu, Arnab and Gupta, Garima and El-Rayes, Bassel and Bae, Sejong and Mattox, Tyler and Hawkins, Cyntanna and Arend, Rebecca C and Akce, Mehmet and Boumber, Yanis and Desai, Aakash},
title = {HER2 alterations across solid tumors: implications for comprehensive testing},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {9},
doi = {10.1093/oncolo/oyaf258}
}
EUVIMED